On September 20, 2023, Forte Biosciences Inc announced that it held its 2023 annual meeting of shareholders on September 19, 2023 and declared the voting Results. Accordingly, nominations made by Camac Partners LLC to appoint Michael G Hacke and Chris McIntyre to the Company board were not appointed, nominations made by the Company to appoint Lawrence Eichenfield and Paul A. Wagner were appointed by the shareholders of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.559 USD | -0.18% | -4.13% | -31.97% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.97% | 20.37M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Declaration of Voting Results by Forte Biosciences